Significant Inhibition of Corneal Scarring In Vivo with Tissue-Selective, Targeted AAV5 Decorin Gene Therapy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: This study tested a hypothesis that tissue-selective targeted decorin gene therapy delivered to the stroma with adeno-associated virus serotype 5 (AAV5) inhibits corneal fibrosis in vivo without significant side effects. METHODS: An in vivo rabbit model of corneal fibrosis was used. Targeted decorin gene therapy was delivered to the rabbit cornea by a single topical application of AAV5 (100 μL; 6.5 × 10(12) μg/mL) onto the bare stroma for 2 minutes. The levels of corneal fibrosis were determined with stereomicroscopy, slit lamp biomicroscopy, α-smooth muscle actin (αSMA), fibronectin, and F-actin immunocytochemistry, and/or immunoblotting. CD11b, F4/80 immunocytochemistry, and TUNEL assay were used to examine immunogenicity and cytotoxicity of AAV5 to the cornea. Transmission electron microscopy (TEM) was used to investigate ultrastructural features. Slot-blot-quantified the copy number of AAV5-delivered decorin genes. RESULTS: Selective decorin delivery into the stroma showed a significant (P < 0.01) decrease in corneal haze (1.3 ± 0.3) compared with the no-decorin-delivered control rabbit corneas (3 ± 0.4) quantified using slit lamp biomicroscopy. Immunostaining and immunoblot analyses detected significantly reduced levels of αSMA, F-actin, and fibronectin proteins (59%-73%; P < 0.001 or <0.01) in decorin-delivered rabbit corneas compared with the no-decorin-delivered controls. The visual clinical eye examination, slit lamp clinical studies, TUNEL, CD11b, and F4/80 assays revealed that AAV5-mediated decorin gene therapy is nonimmunogenic and nontoxic for the cornea. TEM studies suggested that decorin gene delivery does not jeopardize collagen fibrillogenesis as no significant differences in collagen fibril diameter and arrangement were observed in decorin-delivered and no-decorin-delivered control corneas. CONCLUSIONS: Tissue-targeted AAV5-mediated decorin gene therapy is effective and safe for treating corneal fibrosis in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Negative regulation of transforming growth factor-β by the proteoglycan decorin
Yamaguchi, Y., Mann, D. M., & Ruoslahti, E. (1990) · Nature · doi:10.1038/346281a0 · Cited by 1,516
The molecular basis of corneal transparency
Hassell, J. R., & Birk, D. E. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.06.021 · Cited by 557 · cited 1×
“In the cornea, decorin is expressed in the stroma and contributes to the maintenance of clarity and structural integrity of the corneal stroma required for normal vision.(4,24,41) In addition to decorin, other proteoglycans such as biglycan, fibromodulin, mimecan, keratocan, and lumican are expressed in the cornea and…”
BackgroundRada, J. A., Cornuet, P. K., & Hassell, J. R. (1993) · Experimental Eye Research · doi:10.1006/exer.1993.1081 · Cited by 345
Cited by
Progress in corneal wound healing
Ljubimov, A. V., & Saghizadeh, M. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.002 · Cited by 872
The corneal fibrosis response to epithelial–stromal injury
Torricelli, A. A. M., Santhanam, A., Wu, J., Singh, V., & Wilson, S. E. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2014.09.012 · Cited by 289
Serotype survey of AAV gene delivery via subconjunctival injection in mice
Song, L., Llanga, T., Conatser, L. M., Zaric, V., Gilger, B. C., & Hirsch, M. L. (2018) · Gene Therapy · doi:10.1038/s41434-018-0035-6 · Cited by 50
Non-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Metadata
- Authors
- Mohan, R. R., Tandon, A., Sharma, A., Cowden, J. W., & Tovey, J. C. K.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-06-30
- Volume
- 52
- Issue
- 7
- Pages
- 4833
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W1980836692
- Cited by
- 94
- References
- 4
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significant Inhibition of Corneal Scarring In Vivo with Tissue-Selective, Targeted AAV5 Decorin Gene Therapy. https://app.cochat.ai/papers/10.1167/iovs.11-7357
- The paper
- Mohan, R. R., Tandon, A., Sharma, A., Cowden, J. W., & Tovey, J. C. K. (2011). Significant Inhibition of Corneal Scarring In Vivo with Tissue-Selective, Targeted AAV5 Decorin Gene Therapy. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.11-7357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.